Hologic Inc
NASDAQ:HOLX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Hologic Inc
NASDAQ:HOLX
|
16.7B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.4B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
127.3B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.2B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.6B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Hologic Inc
Glance View
Hologic Inc., headquartered in Marlborough, Massachusetts, crafts a narrative deeply intertwined with the vital mission of women's health. Established in 1985, the company has grown into a prominent player in the medical device and diagnostics realm. Hologic’s success is anchored in its core business sectors: Breast & Skeletal Health, Diagnostic Solutions, GYN Surgical, and Medical Aesthetics. The cornerstone of this expansive operation is innovation, driving the development of advanced technologies like 3D mammography systems that revolutionize breast cancer detection. This strategic focus on high-value diagnostics and medical equipment allows Hologic to capture significant market share, ensuring a steady revenue stream from both capital equipment sales and ongoing service and maintenance contracts. Beyond its robust presence in imaging and diagnostics, Hologic amplifies its influence through a comprehensive array of solutions for early stage disease detection and treatment. Their Diagnostic Solutions arm, particularly strengthened by molecular diagnostic tests, is a response to the increasing global demand for rapid and accurate testing solutions—a need only intensified by recent global health challenges. These products not only provide critical tools for healthcare professionals but also secure recurring income for Hologic through the sale of consumables and tests. By embedding itself in the cycles of medical advancements and enhancing the standard of care, Hologic generates sustainable growth and remains a crucial ally in both public and specialized health sectors. The company’s blend of technology-driven products and strategic agility enables it to navigate dynamic markets while maintaining a resolute focus on improving health outcomes around the world.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Hologic Inc is 56.5%, which is above its 3-year median of 56.1%.
Over the last 3 years, Hologic Inc’s Gross Margin has decreased from 59.3% to 56.5%. During this period, it reached a low of 55.1% on Mar 30, 2024 and a high of 59.3% on Dec 31, 2022.